Autologous activated platelet‐rich plasma in hair growth: A pilot study in male androgenetic alopecia with in vitro bioactivity investigation

2020 ◽  
Author(s):  
Yinghui Zhou ◽  
Qingmei Liu ◽  
Yanshuang Bai ◽  
Kai Yang ◽  
Yaqi Ye ◽  
...  
Keyword(s):  
Pilot Study ◽  
Hair Growth ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
In Vitro Bioactivity

scholarly journals Growth factor concentrations in platelet‐rich plasma for androgenetic alopecia: An intra‐subject, randomized, blinded, placebo‐controlled, pilot study

2020 ◽  
Vol 29 (3) ◽  
pp. 334-340 ◽  
Author(s):  
Tee Wei Siah ◽  
Hongwei Guo ◽  
Thomas Chu ◽  
Leopoldo Santos ◽  
Hisae Nakamura ◽  
...  
Keyword(s):  
Pilot Study ◽  
Growth Factor ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia

ANALYSIS OF EXPEDIENCY TO USE PLATELET-ENRICHED PLASMA FOR TREATMENT OF ANDROGENETIC ALOPECIA

2020 ◽  
pp. 64-67
Author(s):  
Yu. S. Ovcharenko ◽  
O. A. Salyenkova
Keyword(s):  
Growth Factors ◽  
Hair Growth ◽  
Platelet Rich Plasma ◽  
Biological Effects ◽  
Practical Experience ◽  
Biologically Active ◽  
Androgenetic Alopecia ◽  
Published Data ◽  
Active Components ◽  
Characteristic Features

A detailed analysis of the published data on the use of platelet−enriched plasma for the treatment of androgenetic alopecia has been performed. Based on the results, it has been suggested that platelet−rich plasma may be considered as a new treatment for pathological hair−related conditions, including androgenetic alopecia. Information on platelet morphology, characteristics of biologically active substances released from activated platelets have been provided. It has been substantiated that platelets play a crucial role in hemostasis and tissue regeneration by stimulating the cell chemotaxis, proliferation, differentiation, angiogenesis and deposition of the extracellular matrix. Among the many active components of platelets involved into the recovery of damaged tissue, the growth factors have been particularly noted. The influence of growth factors on the regulation of hair growth cycles has been established. Based on the analysis of their biological effects, the diversity of their action in the regulation of hair growth has been emphasized. Characteristic features of some growth factors, insulin−like growth factor (IGF), have been determined and described, their role in damaged tissue repair, angiogenesis, proliferation and cell differentiation has been noted. The practical experience of application of platelet−enriched plasma in various branches of medicine is summarized, proposals concerning the use of this method as a new way of treatment of androgenetic alopecia have been provided. The question of standardization of this method, study and substantiation of differentiated use of platelet−enriched plasma depending on the stage of androgenetic alopecia in men and women remains debatable. Key words: androgenetic alopecia, platelet−enriched plasma, platelets, growth factors.

scholarly journals Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation

Biomedicines ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 27 ◽  
Author(s):  
Pietro Gentile ◽  
Maria G. Scioli ◽  
Alessandra Bielli ◽  
Barbara De Angelis ◽  
Ciro De Sio ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Growth Factors ◽  
Hair Growth ◽  
Cellular Proliferation ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Dermal Papilla Cells ◽  
Molecular Pathway ◽  
Baseline Values

Platelet rich plasma (PRP) and Micrografts containing human follicle mesenchymal stem cells (HF-MSCs) were tried as a potential treatment for androgenetic alopecia (AGA). However, little to no work has yet to be seen wherein the bio-molecular pathway of HF-MSCs or PRP treatments were analyzed. The aims of this work are to report the clinical effectiveness of HF-MSCs and platelet-rich plasma evaluating and reviewing the most updated information related to the bio-molecular pathway. Twenty-one patients were treated with HF-MSCs injections and 57 patients were treated with A-PRP. The Wnt pathway and Platelet derived-growth factors effects were analyzed. 23 weeks after the last treatment with mean hair thickness increments (29 ± 5.0%) over baseline values for the targeted area. 12 weeks after the last injection with A-PRP mean hair count and hair density (31 ± 2%) increases significantly over baseline values. The increment of Wnt signaling in Dermal Papilla Cells evidently is one of the principal factors that enhances hair growth. Signaling from mesenchymal stem cells and platelet derived growth factors positively influences hair growth through cellular proliferation to prolong the anagen phase (FGF-7), inducing cell growth (ERK activation), stimulating hair follicle development (β-catenin), and suppressing apoptotic cues (Bcl-2 release and Akt activation).

scholarly journals Increased Expression of Zyxin and Its Potential Function in Androgenetic Alopecia

2021 ◽  
Vol 8 ◽  
Author(s):  
Qingmei Liu ◽  
Xiangguang Shi ◽  
Yue Zhang ◽  
Yan Huang ◽  
Kai Yang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hair Follicle ◽  
Hair Growth ◽  
Ex Vivo ◽  
Cell Activity ◽  
Hair Follicles ◽  
Androgenetic Alopecia ◽  
Pcr Analysis

Androgenetic alopecia (AGA) is the most common progressive form of hair loss, occurring in more than half of men aged > 50 years. Hair follicle (HF) miniaturization is a feature of AGA, and dermal papillae (DP) play key roles in hair growth and regeneration by regulating follicular cell activity. Previous studies have revealed that adhesion signals are important factors in AGA development. Zyxin (ZYX) is an actin-interacting protein that is essential for cell adhesion and migration. The aim of this research was to investigate the expression and potential role of ZYX in AGA. Real-time polymerase chain reaction (RT-PCR) analysis revealed that ZYX expression was elevated in the affected frontal HF of individuals with AGA compared to unaffected occipital HF. Moreover, increased ZYX expression was also observed within DP using immunofluorescence staining. Our in vivo results revealed that ZYX knockout mice showed enhanced hair growth and anagen entry compared to wild-type mice. Reducing ZYX expression in ex vivo cultured HFs by siRNA resulted in the enhanced hair shaft production, delayed hair follicle catagen entry, increased the proliferation of dermal papilla cells (DPCs), and upregulated expression of stem cell-related proteins. These results were further validated in cultured DPCs in vitro. To further reveal the mechanism by which ZYX contributes to AGA, RNA-seq analysis was conducted to identify gene signatures upon ZYX siRNA treatment in cultured hair follicles. Multiple pathways, including focal adhesion and HIF-1 signaling pathways, were found to be involved. Collectively, we discovered the elevated expression of ZYX in the affected frontal hair follicles of AGA patients and revealed the effects of ZYX downregulation on in vivo mice, ex vivo hair follicles, and in vitro DPC. These findings suggest that ZYX plays important roles in the pathogenesis of AGA and stem cell properties of DPC and may potentially be used as a therapeutic target in AGA.

The Therapeutic Response of Platelet Rich Plasma (PRP) for Androgenetic Alopecia Showed No Correlation with Growth Factors and Platelet Number

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2637-2637 ◽  
Author(s):  
Bruno Lima Rodrigues ◽  
Silmara Aparecida De Lima Montalvão ◽  
Joyce Annichinno-Bizzacchi ◽  
Rebeca Cancela ◽  
Francesca Silva ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Hair Loss ◽  
Hair Growth ◽  
Therapeutic Response ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Autologous Serum ◽  
Platelet Number ◽  
The Mean

Abstract Background: Androgenetic alopecia (AGA) is characterized by a pattern hair loss. Currently, treatment with platelet-rich plasma (PRP) has shown promising results due to the growth factors (GFs) released by the platelets. However, the analysis of therapeutic response according to GFs levels and platelet number in PRP has not been established. Objective: Investigate the therapeutic response to treatment of AGA using a standard method of PRP preparation, and the relation with GFs levels and platelet number. Methods: Inclusion criteria comprised diagnosis of AGA-III-vertex profile according to the Norwood-Hamilton scale, age between 18 and 50 years. Exclusion criteria comprised female gender, previous hair transplantation, any disease related to hair loss such as thyroid disease and/or iron deficiency, neoplasia present or past, kidney, liver, infectious, hematologic or rheumatoid disease, use of antiplatelet and/or anti-inflammatory drugs. All patients provided written informed consent approved by the ethic committee from the Faculty of Medical Sciences of the State University of Campinas (UNICAMP). The protocol comprised 20 subcutaneous injections of 100 µL in the scalp totaling 4 applications every fifteen days, with evaluation performed pretreatment (t0), 45 (t1) and 150 (t2) days after the start of the protocol. The endpoints for therapeutic response were hair growth and increase of percentage of anagen hairs evaluated by TrichoScan. For each patient 40 mL of peripheral blood were collected in ACD tubes. L-PRP (PRP with leukocytes) was performed, with double centrifugation (300 g for 5 minutes, and 700 g for 17 minutes). The platelets were counted in the baseline and in the PRP samples. PRP was activated with autologous serum. The platelet-derived growth factors (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) were measured by Luminex technique (Millipore®, USA), in two different PRP samples from each patient. Results: During the period of August to December of 2014, 15 male patients were included in the study. The median of platelets in PRP was increased by 5 folds in all four PRP preparations with a minimum of 728.9 and maximum 1.901,90 x 106 cel/uL, and median values of 1.082 x 106 cel/uL (range 608 - 2.023). The baseline number of platelets and PRP preparation showed a significant correlation (r = 0.839, p < 0.0001). The variability of platelet numbers from each individual during the four applications was 19.7% with a minimum of 0.50% and a maximum 56.3%. GF quantification of two different PRP preparations showed a similar intra-individual variation, with a mean of variability coefficient of 18.4% for VEGF, 20.9% for PDGF, and 21.6% for EGF (Table 1). EGF and PDGF concentrations showed a significant correlation to PRP platelets number (r = 0.8287 and P < 0.0001, and r = 0.6925 and P=0.0014, respectively) (Figure 1). Our results showed a significant increase in hair count (P = 0.0018) and anagen hairs (P = 0.0070) in 86.6% and 53.3% of patients, respectively. However, no correlation was found between platelet counts and GFs levels with therapeutic response. The patients who presented high levels of GFs did not show better results for hair growth or anagen hair than who presented lower levels. Conclusion: Our results corroborate previous studies that showed PRP as a quite promising therapeutic option for AGA, up to 3 months after the injections. However, there was a lack of correlation between the therapeutic responses and platelet numbers or GFs levels. Although, the GFs were not considered biomarker for PRP, it may play an important role in the PRP therapeutic effect. In addition, our results suggest that the PRP effects depend on an orchestration between many mechanisms involved in the increase of number of hairs and its growth. Furthermore, local receptors might present a central role in this response. Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document